Matthew K. Doan

Matthew K. Doan

Auto-generated profile, based on publicly available information

Matthew K. Doan

From Mayo Clinic Alix School of Medicine, 5777 East Mayo Blvd, Scottsdale, AZ 85054 (M.K.D., E.V.); and Departments of Radiology (J.R.L., A.W., J.A.F.) and Orthopedic Surgery (K.P.), Mayo Clinic Arizona, Phoenix, Ariz

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
DHDina V. Hingorani
Dina V. Hingorani
MDMatthew K. Doan
Matthew K. Doan
MCMaria F. Camargo
Maria F. Camargo
JAJoseph Aguilera
Joseph Aguilera
SSSeung M. Song
Seung M. Song
SASunil Advani
Sunil Advani
The most successful therapeutic strategies for locally advanced cancers continue to combine decades-old classical radiosensitizing chemotherapies with radiotherapy. Molecular targeted radiosensitizers offer the potential to improve the therapeutic ratio by increasing tumor-specific kill while minimizing drug delivery and toxicity to surrounding normal tissue. Auristatins are a potent class of anti-tubulins that sensitize cells to ionizing radiation damage and are chemically amenable to antibody conjugation. To achieve tumor-selective radiosensitization, we synthesized and tested anti-HER2 antibody–drug conjugates of two auristatin derivatives with ionizing radiation. Monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) were attached to the anti-HER2 antibodies trastuzumab and pertuzumab through a cleavable linker. While MMAE is cell permeable, MMAF has limited cell permeability as free drug resulting in diminished cytotoxicity and radiosensitization. However, when attached to trastuzumab or pertuzumab, MMAF was as efficacious as MMAE in blocking HER2-expressing tumor cells in G2–M. Moreover, MMAF anti-HER2 conjugates selectively killed and radiosensitized HER2-rich tumor cells. Importantly, when conjugated to targeting antibody, MMAF had the advantage of decreased bystander and off-target effects compared with MMAE. In murine xenograft models, MMAF anti-HER2 antibody conjugates had less drug accumulated in the normal tissue surrounding tumors compared with MMAE. Therapeutically, systemically injected MMAF anti-HER2 conjugates combined with focal ionizing radiation increased tumor control and improved survival of mice with HER2-rich tumor xenografts. In summary, our results demonstrate the potential of cell-impermeable radiosensitizing warheads to improve the therapeutic ratio of radiotherapy by leveraging antibody–drug conjugate technology.

1 December 2021 in World Neurosurgery
Verified
Journal Article
Closed access
MMM. Lane Moore
M. Lane Moore
RSRohin Singh
Rohin Singh
KMKyli McQueen
Kyli McQueen
MDMatthew K. Doan
Matthew K. Doan
HDHarjiven Dodd
Harjiven Dodd
NPNaresh P. Patel
Naresh P. Patel

1 March 2024 in RadioGraphics
Verified
Journal Article
Closed access
MDMatthew K. Doan
Matthew K. Doan
JLJeremiah R. Long
Jeremiah R. Long
EVErik Verhey
Erik Verhey
AWAaron Wyse
Aaron Wyse
KPKaran Patel
Karan Patel
JFJonathan A. Flug
Jonathan A. Flug
Cone-beam CT (CBCT) is a promising tool with increasing applications in musculoskeletal imaging due to its ability to provide thin-section CT images of the appendicular skeleton and introduce weight bearing, which accounts for loading forces that typically interact with and affect this anatomy. CBCT devices include an x-ray source directly opposite a digital silicon detector panel that performs a single rotation around an object of interest, obtaining thin-section images. Currently, the majority of research has been focused on the utility of CBCT with foot and ankle pathologic abnormalities, due to the complex architectural arrangement of the tarsal bones and weight-bearing nature of the lower extremities. Associated software can provide a variety of options for image reconstruction, including metal artifact reduction, three-dimensional biometric measurements, and digitally reconstructed radiographs. Advancements in this technology have allowed imaging of the knee, hip, hand, and elbow. As more data are published, it is becoming evident that CBCT provides many additional benefits, including fast imaging time, low radiation dose, lower cost, and small equipment footprint. These benefits allow placement of CBCT units outside of the traditional radiology department, including the orthopedic clinic setting. These technologic developments have motivated clinicians to define the scope of CBCT for diagnostics, surgical planning, and longitudinal imaging. As efforts are made to create standardized protocol and measurements, the current understanding and surgical approach for various orthopedic pathologic conditions will continue to shift, with the hope of improving outcomes. ©RSNA, 2024 Test Your Knowledge questions for this article are available in the supplemental material.

3 April 2023
Verified
Other
Open access
DHDina V. Hingorani
Dina V. Hingorani
MDMatthew K. Doan
Matthew K. Doan
MCMaria F. Camargo
Maria F. Camargo
JAJoseph Aguilera
Joseph Aguilera
SSSeung M. Song
Seung M. Song
SASunil J. Advani
Sunil J. Advani
T-MMAE stability and bystander cytotoxicity in HER2 negative cells.

3 April 2023
Verified
Other
Open access
DHDina V. Hingorani
Dina V. Hingorani
MDMatthew K. Doan
Matthew K. Doan
MCMaria F. Camargo
Maria F. Camargo
JAJoseph Aguilera
Joseph Aguilera
SSSeung M. Song
Seung M. Song
SASunil J. Advani
Sunil J. Advani
The most successful therapeutic strategies for locally advanced cancers continue to combine decades-old classical radiosensitizing chemotherapies with radiotherapy. Molecular targeted radiosensitizers offer the potential to improve the therapeutic ratio by increasing tumor-specific kill while minimizing drug delivery and toxicity to surrounding normal tissue. Auristatins are a potent class of anti-tubulins that sensitize cells to ionizing radiation damage and are chemically amenable to antibody conjugation. To achieve tumor-selective radiosensitization, we synthesized and tested anti-HER2 antibody–drug conjugates of two auristatin derivatives with ionizing radiation. Monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) were attached to the anti-HER2 antibodies trastuzumab and pertuzumab through a cleavable linker. While MMAE is cell permeable, MMAF has limited cell permeability as free drug resulting in diminished cytotoxicity and radiosensitization. However, when attached to trastuzumab or pertuzumab, MMAF was as efficacious as MMAE in blocking HER2-expressing tumor cells in G2–M. Moreover, MMAF anti-HER2 conjugates selectively killed and radiosensitized HER2-rich tumor cells. Importantly, when conjugated to targeting antibody, MMAF had the advantage of decreased bystander and off-target effects compared with MMAE. In murine xenograft models, MMAF anti-HER2 antibody conjugates had less drug accumulated in the normal tissue surrounding tumors compared with MMAE. Therapeutically, systemically injected MMAF anti-HER2 conjugates combined with focal ionizing radiation increased tumor control and improved survival of mice with HER2-rich tumor xenografts. In summary, our results demonstrate the potential of cell-impermeable radiosensitizing warheads to improve the therapeutic ratio of radiotherapy by leveraging antibody–drug conjugate technology.

3 April 2023
Verified
Other
Open access
DHDina V. Hingorani
Dina V. Hingorani
MDMatthew K. Doan
Matthew K. Doan
MCMaria F. Camargo
Maria F. Camargo
JAJoseph Aguilera
Joseph Aguilera
SSSeung M. Song
Seung M. Song
SASunil J. Advani
Sunil J. Advani
MMAF anti-HER2 antibody conjugates spatial localization in HER2 negative tumors.